How The IRA Factored Into Akebia’s Price For Vafseo
CSL Vifor Deal Converted To Royalty Agreement
Akebia said it had set the price for Vafseo at about $15,500 per year, meant to reflect its potential value in dialysis as well as eventually in non-dialysis patients.
